Business Wire

W-INITIATIVE

1.6.2022 13:27:08 CEST | Business Wire | Press release

Share
Casper Ruud Appointed Global Ambassador for W Initiative

Norway’s best tennis player and superstar Casper Ruud (23) is the new global ambassador for the Norwegian humanitarian foundation W Initiative. The agreement involves a close partnership over the next three years.

W Initiative was established in 2021 by SalMar heir Gustav Magnar Witzoe (29), to support humanitarian activities that improve the quality of life for children and young people around the world.

“I am proud to promote W Initiative on an international arena. I can think of nothing more meaningful than to help children and young people have a better live, better health and more equal opportunities, which also includes games and sports,” says Casper Ruud, who is currently competing in the French Open Grand Slam tournament.

Long-term partnership
As ambassador, Casper Ruud will be promoting the foundation and making it more visible to an international audience. This includes wearing the W Initiative logo on his clothing, talking about the foundation’s work during interviews, in social media and on his own website, as well as participating in various events organised by the foundation. The goal for the W Initiative is to be more visible and, consequently, receive information about and access to new projects around the world that it can support.

“The foundation actively searches for projects around the world that align with key sustainability goals. Having Casper Ruud as an ambassador will open more doors and we can reach international audiences in a completely different way,” explains Managing Director of the foundation Eirik Boe Sletten.

Gustav Magnar Witzoe created W Initiative in 2021 and it is Witzoe’s company Forward Project that is funding the partnership with Casper Ruud, which starts on 1 June and lasts until the end of 2024. W Initiative will then have the preferential right to extend the partnership for another two years.

The right man
“When I first met Casper, it was immediately clear that he was the right ambassador for the foundation – not only because he is one of the world’s best athletes who plays on the world’s premiere arenas, but also because he is simply a great guy who shares the foundation’s values and views. His contribution comes at an important time in the evolution of the foundation. If this partnership can also contribute positively to his own development as Norway’s best tennis player, that’s fantastic,” says Witzoe.

Witzoe comes from a small rural Island off the west coast of Norway with a population of just over 4000. His father pioneered the fish farming industry, in time becoming one of the world’s most successful in the industry, with his company SalMar.

W Initiative aims to grow through effective management and expansion to make increasingly meaningful contributions.

“Our first project in Uganda, which is being carried out together with Right To Play, contributes to better water and sanitary conditions, in addition to games and sports for children in three districts in the country. We have also joined a new project in Fiji headed by FijiStiftelsen. Thanks to the support of the W Initiative, FijiStiftelsen will be building two evacuation centres that will be used daily as a classroom and multipurpose room for children, as well as give women the opportunity to create their own workplace,” explains Boe Sletten.

Download pictures here: Pictures

More info here: https://www.w-initiative.com/en

W Initiative facts and figures

W Initiative is a newly established humanitarian foundation that aims to improve the quality of life of children and young people. The projects supported by the foundation may be in Norway or elsewhere but must always be grounded in UN Sustainable Development Goals 3, 4, 5, 6 or 10. The projects must have a focus on increased competence, better health, and more equal opportunities. Gustav Magnar Witzoe has donated NOK 110 million to the foundation through his family-owned company, of which NOK 100 million is earmarked for the foundation’s founding capital to enable increasingly meaningful contributions through effective management and expansion. The foundation will actively seek out projects that align with its vision and purpose and it will not be possible to apply for funding from the foundation. The foundation wishes to work together with well-established organisations. An annual report will be published on status and progress based on the foundation’s objectives.

Management board

Witzoe is the son of SalMar founder Gustav Witzoe and is currently the majority shareholder of the parent company Kvarv AS. The management board also includes NTNU professor Heri Ramampiaro, associate attorney Kristina Jorgensen, chief physician Elisabeth Vesterbekkmo and civil engineer Magnus Witzoe. All board members have a different background, but with a strong affiliation with Trondelag.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye